Office Portfolios Safety 
The Dermatology Digest
DECEMBER 18, 2024
The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). . immunology market.”
Southeastern Esthetics Institute
AUGUST 23, 2016
Specific courses for cosmetic lasers, for example, are crucial to add to the esthetics portfolio, in order to showcase added training beyond that of the esthetics fundamentals course. A complete system must be in place per office, for the role of every action within the practice.
The Dermatology Digest
MARCH 5, 2024
The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. Chief Executive Officer of Apogee, in a news release. . Chief Executive Officer of Apogee, in a news release. “We
Aesthetics Advisor
SEPTEMBER 15, 2023
It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. There is a growing body of data that sprays, in particular Xlear, can help combat the COVID-19 pandemic.
The Dermatology Digest
NOVEMBER 4, 2024
The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.
The Dermatology Digest
APRIL 16, 2025
With the introduction of Evolysse, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.
The Dermatology Digest
FEBRUARY 13, 2025
This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.
Expert insights. Personalized for you.
69 
Let's personalize your content